Workflow
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
Globenewswireยท2025-06-24 13:00

Core Points - Vivoryon Therapeutics N.V. held its Annual General Meeting (AGM) on June 24, 2025, where shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer as an executive director [2] - The re-appointment of Dr. Frank Weber and Anne Doering as executive directors, along with the re-appointment of Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah as non-executive directors, was also confirmed [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease [3] - The company's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]